Skip to content

Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC

Evaluation of Diagnostic and Differential Diagnostic Significance of a Combination of PIVKA-II and Other Tumor Markers in Hepatocellular Carcinoma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03047603
Enrollment
4005
Registered
2017-02-09
Start date
2016-05-01
Completion date
2019-03-20
Last updated
2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular carcinoma, Protein induced by vitamin K absence or antagonist-II, Differential diagnosis, Des-γ-carboxy prothrombin, Alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein-fetoprotein

Brief summary

The incidence of Hepatocellular carcinoma (HCC) is increasing worldwide. However, most of HCC cases were at advanced stage when the diagnosis established.Early diagnosis improves the prognosis.The study is intended to evaluate the diagnostic efficiency of Protein Induced by Vitamin K Absence or antagonist-II(PIVKA-II). This study is a international multicenter study joined by several hospitals in China,Singapore,Thailand and Vietnam. Participants including healthy control,HCC,metastatic liver cancer,Hepatitis B virus(HBV) and liver cirrhosis are consecutively recruited into the cohort. All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum samples were tested for PIVKA-II,alpha-fetoprotein and biochemical indexes including alanine aminotransferase(ALT),aspartate aminotransferase(AST),gamma-glutamyl transferase(GGT),alpha-l-fucosidase(AFU),etc.

Detailed description

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide.Early diagnosis improves the prognosis. Protein induced by vitamin K antagonist-II (PIVKA-II), also known as des-γ-carboxyprothrombin (DCP) or acarboxy prothrombin, is an abnormal form of prothrombin induced by vitamin K absence or antagonist-II. The study is intended to evaluate the diagnostic efficiency of Protein Induced by Vitamin K Absence or antagonist-II(PIVKA-II). PIVKA-II as an effective tumor marker for hepatocellular carcinoma(HCC) has been widely used in the western countries where most cases are hepatitis C virus(HCV) related.However, the majority of HCCs in China are HBV related. Despite the extensive application of PIVKA-II in some hospitals from China, the diagnostic efficiency including sensitivity,specificity,positive predictive value and negative predictive value still needs more clinical data to evaluate. The research purposes list as follows:1.Determination of diagnostic Cut-off value 2.Evaluation of diagnostic efficiency of PIVKA-II 3.Evaluation of the combination of PIVKA-II and other tumor markers for HCC. This study is an international multicenter study joined by several hospitals in China,Singapore,Thailand and Vietnam. Participants including healthy control,HCC,metastatic liver cancer,HBV and liver cirrhosis are consecutively recruited into the cohort. All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum samples were tested for PIVKA-II,Alpha-fetoprotein(AFP),alpha-fetoprotein L3 and biochemical indexes including ALT,AST,GGT,AFU,etc. The diagnosis of HCC was based on histopathology. All HCC diagnoses were confirmed at the time of analysis.The Student's t-test (or Mann-Whitney test) was used to compare continuous variables, and the chi-square test (or Fisher's exact test) was used for categorical variables. A receiver operator characteristic (ROC) curve was used to assess the performance characteristic of PIVKA-II,AFP,AFP-L3 measurement.

Interventions

DIAGNOSTIC_TESTPIVKA-II

Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.

Sponsors

Abbott Diagnostics Division
CollaboratorINDUSTRY
Peking University First Hospital
CollaboratorOTHER
The First Hospital of Jilin University
CollaboratorOTHER
RenJi Hospital
CollaboratorOTHER
First Affiliated Hospital Xi'an Jiaotong University
CollaboratorOTHER
Gansu Provincial Hospital
CollaboratorOTHER
Henan Provincial People's Hospital
CollaboratorOTHER
Sun Yat-sen University
CollaboratorOTHER
Sichuan Provincial People's Hospital
CollaboratorOTHER
Eastern Hepatobiliary Surgery Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years

Inclusion criteria

* Age between 18 and 85 * Receiving no treatment before diagnosis * Establishing Diagnosis according to the Asian Pacific Association for the Study of Liver(APASL) criteria

Exclusion criteria

* Clinical data missing * Laboratory tests information missing * Serum samples doesn't qualified * Obstructive jaundice patients * Medical history of taking warfarin

Design outcomes

Primary

MeasureTime frameDescription
PIVKA-IIDay oneUsing PIVKA-II assay kit(chemiluminescent microparticle immunoassay).

Secondary

MeasureTime frame
AFP,AFP-L3%Day one
ALT, AST,γ-GT, AFUDay one

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026